Should we stop using intravenous gentamicin in patients with cystic fibrosis?

Thorax

Volumn 63, Issue 6, 2008, Pages 479-480

  Goss, Christopher H ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GENTAMICIN; TOBRAMYCIN;

ACUTE KIDNEY FAILURE; CONFIDENCE INTERVAL; CREATININE CLEARANCE; CYSTIC FIBROSIS; EDITORIAL; HEALTH SURVEY; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL;

ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CYSTIC FIBROSIS; GENTAMICINS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, ACUTE;

EID: 45149089142     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2007.094821     Document Type: Editorial

References (26)

1. Cystic Fibrosis Foundation. Patient Registry 2006: annual data report. Bethesda, MD: Cystic Fibrosis Foundation, 2007.
2. Dodge JA, Lewis PA, Stanton M, et al. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007;29:522-6.
3. Bellis G, Cazes MH, Parant A, et al. Cystic fibrosis mortality trends in France. J Cyst Fibros 2007;6:179-86.
4. Slieker MG, Uiterwaal CS, Sinaasappel M, et al. Birth prevalence and survival in cystic fibrosis: a national cohort study in the Netherlands. Chest 2005;128:2309-15.
5. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30.
6. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637-42.
7. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-56.
8. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-40.
9. Morales MM, Carroll TP, Morita T, et al. Both the wild type and a functional isoform of CFTR are expressed in kidney. Am J Physiol 1996;270:F1038-48.
10. Smyth A, Lewis S, Bertenshaw C, et al. Case-control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2008;63:532-5.
11. Bertenshaw C, Watson AR, Lewis S, et al. Survey of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2007;62:541-5.
12. Moffett BS, Rosenstein BJ, Mogayzel PJ Jr. Ciprofloxacin-induced renal insufficiency in cystic fibrosis. J Cyst Fibros 2003;2:152-4.
13. Bald M, Ratjen F, Nikolaizik W, et al. Ciprofloxacin- induced acute renal failure in a patient with cystic fibrosis. Pediatr Infect Dis J 2001;20:320-1.
14. Hoffmann IM, Rubin BK, Iskandar SS, et al. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr Pulmonol 2002;34:375-7.
15. Drew J, Watson AR, Smyth A. Acute renal failure and cystic fibrosis. Arch Dis Child 2003;88:646.
16. Al-Aloul M, Miller H, Stockton P, et al. Acute renal failure in CF patients chronically infected by the Liverpool epidemic Pseudomonas aeruginosa strain (LES). J Cyst Fibros 2005;4:197-201.
17. Al-Aloul M, Miller H, Alapati S, et al. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005;39:15-20.
18. Schulz KF, Grimes DA. Case-control studies: research in reverse. Lancet 2002;359:431-4.
19. Grimes DA, Schulz KF. Compared to what? Finding controls for case-control studies. Lancet 2005;365:1429-33.
20. Bjerre LM, LeLorier J. Expressing the magnitude of adverse effects in case-control studies: "the number of patients needed to be treated for one additional patient to be harmed". BMJ 2000;320:503-6.
21. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philidelphia: Lippincott-Raven Publishers, 1998.
22. Olson SH, Voigt LF, Begg CB, et al. Reporting participation in case-control studies. Epidemiology 2002;13:123-6.
23. Sorensen HT, Gillman MW. Matching in case-control studies. BMJ 1995;310:329-30.
24. Greenland S. The effect of misclassification in matched-pair case-control studies. Am J Epidemiol 1982;116:402-6.
25. Thomas DC, Greenland S. The relative efficiencies of matched and independent sample designs for case-control studies. J Chronic Dis 1983;36:685-97.
26. Garabrant DH. Case-control study design: spurious associations between exposure and outcome. J Occup Environ Med 2007;49:941-2.